Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Aug;95(8):e29010.
doi: 10.1002/jmv.29010.

Effectiveness of prolonged versus standard-course of oseltamivir in critically ill patients with severe influenza infection: A multicentre cohort study

Gerard Moreno  1 , Raquel Carbonell  1 , Emili Díaz  2 , Ignacio Martín-Loeches  3 , Marcos I Restrepo  4 , Luis F Reyes  5 , Jordi Solé-Violán  6 , María Bodí  1   7 , Laura Canadell  8 , Juan Guardiola  9 , Sandra Trefler  1 , Loreto Vidaur  10 , Elisabeth Papiol  11 , Lorenzo Socias  12 , Eudald Correig  13 , Judith Marín-Corral  14 , Alejandro Rodríguez  1   7 ; GETGAG Working Group
Affiliations
Multicenter Study

Effectiveness of prolonged versus standard-course of oseltamivir in critically ill patients with severe influenza infection: A multicentre cohort study

Gerard Moreno et al. J Med Virol. 2023 Aug.

Abstract

The aim of this study is to investigate the effectiveness of prolonged versus standard course oseltamivir treatment among critically ill patients with severe influenza. A retrospective study of a prospectively collected database including adults with influenza infection admitted to 184 intensive care units (ICUs) in Spain from 2009 to 2018. Prolonged oseltamivir was defined if patients received the treatment beyond 5 days, whereas the standard-course group received oseltamivir for 5 days. The primary outcome was all-cause ICU mortality. Propensity score matching (PSM) was constructed, and the outcome was investigated through Cox regression and RCSs. Two thousand three hundred and ninety-seven subjects were included, of whom 1943 (81.1%) received prolonged oseltamivir and 454 (18.9%) received standard treatment. An optimal full matching algorithm was performed by matching 2171 patients, 1750 treated in the prolonged oseltamivir group and 421 controls in the standard oseltamivir group. After PSM, 387 (22.1%) patients in the prolonged oseltamivir and 119 (28.3%) patients in the standard group died (p = 0.009). After adjusting confounding factors, prolonged oseltamivir significantly reduced ICU mortality (odds ratio [OR]: 0.53, 95% confidence interval [CI]: 0.40-0.69). Prolonged oseltamivir may have protective effects on survival at Day 10 compared with a standard treatment course. Sensitivity analysis confirmed these findings. Compared with standard treatment, prolonged oseltamivir was associated with reduced ICU mortality in critically ill patients with severe influenza. Clinicians should consider extending the oseltamivir treatment duration to 10 days, particularly in higher-risk groups of prolonged viral shedding. Further randomized controlled trials are warranted to confirm these findings.

Keywords: ICU mortality; critically ill; prolonged oseltamivir; severe influenza.

PubMed Disclaimer

References

REFERENCES

    1. Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391(10127):1285-1300. doi:10.1016/S0140-6736(17)33293-2
    1. Chow EJ, Doyle JD, Uyeki TM. Influenza virus-related critical illness: prevention, diagnosis, treatment. Crit Care. 2019;23(1):214. doi:10.1186/s13054-019-2491-9
    1. Moreno G, Rodríguez A, Sole-Violán J, et al. Early oseltamivir treatment improves survival in critically ill patients with influenza pneumonia. ERJ Open Res. 2021;7(1):00888-2020. doi:10.1183/23120541.00888-2020
    1. Lytras T, Mouratidou E, Andreopoulou A, Bonovas S, Tsiodras S. Effect of early oseltamivir treatment on mortality in critically ill patients with different types of influenza: a multiseason cohort study. Clin Infect Dis. 2019;69(11):1896-1902. doi:10.1093/cid/ciz101
    1. Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med. 2014;2(5):395-404. doi:10.1016/S2213-2600(14)70041-4

Publication types

LinkOut - more resources